SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2013
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:
Item 2.02 Results of Operations and Financial Condition.
As previously announced, on January 7, 2013, at the J.P. Morgan Healthcare Conference in San Francisco, California , John McDermott, President and Chief Executive Officer of Endologix, Inc. (the “Company”) presented a corporate overview and financial update, which presentation included a discussion of the Company's preliminary unaudited financial results for the fourth fiscal quarter and for the fiscal year ended December 31, 2012, issued by the Company on December 7, 2013. The presentation was announced by a widely disseminated press release and was made available to the public via audio webcast. A transcript of the presentation is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.